Mark Weiss, M.D., has been appointed Director of the Hematologic Malignancies and Hematopoietic Stem Cell Transplantation Division in the Department of Medical Oncology. He is an internationally respected and renowned expert in the field of hematologic malignancies, particularly CLL and ALL. Dr. Weiss brings more than 20 years of clinical and investigational experience with him to Jefferson.
Dr. Weiss comes to Thomas Jefferson University and Hospital from Memorial-Sloan Kettering Cancer Center where he held the position of Associate Member. Dr. Weiss earned his undergraduate degree from Cornell University and received his MD., from Cornell University Medical Center. He did his residency including a year as Chief Resident at Vanderbilt University, and then completed his fellowship training in hematology and medical oncology at Memorial Sloan-Kettering Cancer Center. After fellowship, he remained on the faculty at Memorial Sloan-Kettering until joining us at Jefferson.
Dr. Weiss was the first to develop the Pentostatin, Cyclophosphamide and Rituximab (PCR) regimen for patients with CLL. This regimen has proven to be extremely efficacious in the treatment of CLL. Chemoimmunotherapy has become one of the standards for treatment of this disease. A significant advantage of the PCR regimen over other chemoimmunotherapy approaches is the ability to deliver all the therapy in one day and the fact that this regimen has been well tolerated even in older patients who typically have more complications with other treatment approaches. This is now a widely used regimen in the hematologic malignancy community.Dr. Weiss has also developed novel approaches to the treatment of adult ALL with high dose cytarabine and mitoxantrone which has demonstrated superiority over standard approaches in randomized clinical trials. Dr. Weiss is board certified in Internal Medicine, Hematology and Medical Oncology. He serves on numerous editorial boards and reviews for journals such as Blood, Cancer Research, and Leukemia.
Dr. Weiss is a highly dedicated clinician, clinical investigator, and educator who will play a pivotal role in building new clinical programs for the treatment of blood related malignancies within the Department of Medical Oncology.
William. Kevin Kelly, DO has been appointed Director of the Solid Tumor Oncology division in the Department of Medical Oncology and Associate Director of Translational Research in the Kimmel Cancer Center. He is an internationally respected expert in the field of urological malignancies, particularly prostate cancer and is also known for his expertise in the design and conduct of clinical trials. Dr. Kelly brings more than 20 years of clinical and investigational experience with him to Jefferson.
Dr. Kelly comes to Thomas Jefferson University and Hospital from Yale University School of Medicine where he held the positions of Associate Professor of Medicine and Surgery, Medical Director of the Clinical Research Service, Director of the Solid Tumor Clinical Investigation Program and Co-Director of the Prostate and Urological Oncology Program. Dr. Kelly earned his undergraduate degree from Emory University and received his DO, from Philadelphia College of Osteopathic Medicine. He did his residency at Albert Einstein Medical Center, and then completed his fellowship training in medical oncology at Memorial-Sloan Kettering Cancer Center. He subsequently was on the faculty at Memorial-Sloan Kettering Cancer Center for fifteen years before joining Yale University.
Dr. Kelly’s main clinical research focus has been in the area of genitourinary cancers, and without question, he has established himself as one of the leading experts in the development of novel treatment strategies and targeted agents for prostate cancer and other urologic cancers. His research has focused on developing novel designs and biomarkers for prostate cancer and has been instrumental in the development of multiple compounds such as microtubule disrupting agents; histone deacetylase inhibitors; and anti-angiogenesis therapies for urologic cancers. He continues to work closely with scientists, as well as with investigators in industry to develop these agents. Dr. Kelly is board certified in Internal Medicine and Medical Oncology. He serves on numerous editorial boards such as Journal of Clinical Oncology, Clinical Prostate Cancer, Nature Clinical Practice Oncology.
Dr. Kelly is a highly dedicated clinician, clinical investigator, and educator who will play a pivotal role in re-shaping and enhancing clinical research within the Kimmel Cancer Center and in building new clinical programs within the Department of Medical Oncology.
Please welcome Dr. Weiss and Dr Kelly to the faculty in the Department of Medical Oncology and the Kimmel Cancer Center.